Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) From Valeant Pharmaceuticals
Posted on: Monday, 14 January 2008, 18:00 CST
CRANBERRY TOWNSHIP, Pa., Jan. 14 /PRNewswire/ -- Three Rivers Pharmaceuticals, LLC finalized acquisition of the hepatitis C drug Infergen from Valeant Pharmaceuticals International . Valeant is receiving $91 million from Three Rivers for the procurement.
"Adding Infergen to our growing portfolio is very exciting," said Donald J. Kerrish, RPh, Three River's president and chief executive officer. "This purchase is only a beginning for Three Rivers' continuous strategy to increase its product offerings through product acquisition and internal product development of pharmaceutical therapies."
Infergen, or consensus interferon, is a bio-optimized, selective and highly potent type 1 interferon alpha originally developed by Amgen and launched in the United States in 1997. It is currently indicated as monotherapy for the treatment of adult patients suffering from chronic hepatitis C viral infections with compensated liver disease and is dosed three times per week.
Important Safety Information
Physicians and patients can obtain additional prescribing information regarding Infergen, including the product's safety profile and the box warning for all interferon alphas regarding neuropsychiatric, autoimmune, ischemic and infectious disorders, by visiting http://www.infergen.com/.
About Three Rivers Pharmaceuticals
Three Rivers Pharmaceuticals is a privately held company headquartered in Cranberry Township, Pennsylvania and focuses on specialized therapies including hepatitis C therapies. Three Rivers is the first drug company to focus on the needs of the emerging specialty market. With its unique experience and understanding of the complex challenges of treating chronic, difficult diseases, Three Rivers is a valuable partner in the healthcare community.
The company's mission is to develop, manufacture, and market the highest quality branded and generic drug products for patients with serious diseases. Three Rivers Pharmaceuticals focuses on specialized therapies because of our extensive knowledge and experience in this area. More information about the company can be found at http://www.3riverspharma.com/.
Three Rivers Pharmaceuticals
CONTACT: Patrick Kerrish of Three Rivers Pharmaceuticals,pkerrish@3riverspharma.com
Web site: http://www.3riverspharma.com/http://www.infergen.com/
Source: PRNewswire
Related Articles
- Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
- Three Rivers Pharmaceuticals(R), LLC Obtains Additional Commercial Rights to Infergen(R) From Amgen Inc.
- Valeant Pharmaceuticals Completes Divestment of Hep-C Drug Infergen(R) to Three Rivers Pharmaceuticals(R), LLC
- Valeant Pharmaceuticals Sells Hep-C Drug Infergen(R) to Three Rivers Pharmaceuticals(R), LLC for $91 Million
- Gilead and Achillion End Hepatitis Drug Development
- Valeant Hepatitis C Drug Misses Efficacy Target
- Three Rivers Pharmaceuticals Announces FDA Final Approval of Ribasphere(R) (Ribavirin, USP) Tablets 600mg, 400mg and 200mg for the Treatment of Chronic Hepatitis C
- Valeant Pharmaceuticals Agrees to Acquire Rights to Hep-C Drug Infergen(R) From InterMune
- Three Rivers Pharmaceuticals Announces FDA Tentative Approval of Ribasphere(R) (Ribavirin, USP) Tablets for the Treatment of Chronic Hepatitis C
 |
 |
User Comments (0)
RSS Feeds